Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07151391 · ClinicalTrials.gov registry record · Phase 2
The Use of Guarana to Treat Fatigue in Patients With Neuroendocrine Tumors and Gynecologic Cancers (Guarana Fatigue)
A Phase 2 study of Gynecologic Cancer and Neuroendocrine Tumors, sponsored by University of Utah.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 86
- Enrollment target
- 1
- Study location
NCT07151391: Recruiting Phase 2 study of Gynecologic Cancer and Neuroendocrine Tumors, sponsored by University of Utah.
NCT07151391 is a Phase 2 study of Gynecologic Cancer and Neuroendocrine Tumors that is actively recruiting participants, run by University of Utah. The registered enrollment target is 86 participants, below the 763-participant average among 55 other Gynecologic Cancer trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07151391, a Phase 2 study of Gynecologic Cancer and Neuroendocrine Tumors, is actively recruiting participants, sponsored by University of Utah.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 86 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this clinical trial is to learn if the drug guarana improves symptoms of fatigue in patients with neuroendocrine tumors and gynecologic cancers
Primary Outcome
To assess the use of guarana to improve symptoms of fatigue in patients with NETs and Gynecologic (Ovarian/Fallopian Tube and Endometrial) cancers and to estimate the Cohen's effect size for planning of the randomized controlled trial in stage II. This outcome measure will report 3 sub-scales (Physical Fatigue Score, Emotional Fatigue Score, and Cognitive Fatigue Score) and two single-item measures (Interference with daily life and Social sequelae score). All of the scales and single-item meas
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Guarana
Study Locations (1)
Utah
- Huntsman Cancer Institute at University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2025-09-03 |
| Est. Completion | 2028-09 |
| Phase | Phase 2 |
What NCT07151391 shows while recruiting
NCT07151391 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 86 participants, a relatively small participant target, below the 763-participant average among 55 other Gynecologic Cancer trials with a reported enrollment target (89% lower).
The record links to 2 conditions, with Gynecologic Cancer appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07151391 reports a single indexed study location in Utah.
Frequently Asked Questions
What is clinical trial NCT07151391 about?
NCT07151391 is a clinical study titled "The Use of Guarana to Treat Fatigue in Patients With Neuroendocrine Tumors and Gynecologic Cancers (Guarana Fatigue)". The purpose of this clinical trial is to learn if the drug guarana improves symptoms of fatigue in patients with neuroendocrine tumors and gynecologic cancers
What is the current status of trial NCT07151391?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 86 participants. The study started on 2025-09-03. Estimated completion is 2028-09.
What conditions does trial NCT07151391 study?
This clinical trial studies the following conditions: Gynecologic Cancer, Neuroendocrine Tumors.
What interventions are being tested in trial NCT07151391?
The interventions under investigation include: Placebo (DRUG), Guarana (DRUG).
Who is sponsoring clinical trial NCT07151391?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07151391 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gynecologic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07151391's enrollment target sits among peer trials
86 24th of 55 higher than 32 of 55 other Gynecologic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gynecologic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
RECRUITING · Phase 2
-
Clinical Investigation of the Effects of Semiconductor Embedded Therapeutic Garments on Cancer-related Cognitive Impairment in Breast and Gynecological Cancer Patients
RECRUITING · Phase 2
-
Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin
RECRUITING · Phase 2
-
Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Pembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01639508 · 86 participants · Phase 2
Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
- NCT03519269 · 86 participants · NA
Navio Robotic Versus Conventional Total Knee Arthroplasty
- NCT04132999 · 86 participants · NA
PAP for Children With DS and OSAS
- NCT04545957 · 86 participants · NA
Jump: MR Simulation For Radiation Therapy Master Protocol
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI